A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 12 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 29 Jun 2017 Planned End Date changed from 1 Jul 2017 to 6 Jul 2017.
    • 29 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 6 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top